You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Cellular Therapies
409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Edelstein JN, Hill TF, Leiken MD, et al
409 Development of ex vivo precision gene engineered B cell medicines that produce highly active and sustained levels of transgenic anti-tumor biologics
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0409